Novartis's EU Zykadia approval fills NSCLC treatment gap
This article was originally published in Scrip
Executive Summary
Novartis's lung cancer drug Zykadia (ceritinib) has been given the green light in Europe. The European Medicines Agency's scientific committee, the CHMP, granted a positive opinion in February this year for Zykadia, to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib (Pfizer's Xalkori). It is now the first specifically approved treatment option for this patient population.